Skip to main content
SpringerLink
Log in

Cancer Vaccines for HPV Malignancies

  • Chapter
  • First Online:
Oncoimmunology

Abstract

On a global scale, approximately one in six new cancer diagnoses is attributable to a specific infectious pathogen. Human papillomaviruses (HPVs) cause approximately 30% of infection-associated cancers, including cancers of the cervix, vagina, vulva, anus, and oropharynx, and nearly 5% of all cancers worldwide. In women, the majority of HPV-induced cancers are cervical cancers; in men, most HPV-associated malignancies are oropharyngeal. Despite the availability of preventive HPV vaccines, and screening methods to detect HPV in the lower genital tract, cervical cancer is the second most common cause of cancer death in women in low-resource settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.

    Article  PubMed  Google Scholar 

  2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.

    Article  PubMed  Google Scholar 

  3. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795–808.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132(2):277–84.

    Article  CAS  PubMed  Google Scholar 

  6. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.

    Article  CAS  PubMed  Google Scholar 

  7. Woodman CBJ, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–6.

    Article  CAS  PubMed  Google Scholar 

  8. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl 3):S3/42–51.

    Google Scholar 

  9. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007;107(2 Suppl 1):S2–5.

    Article  CAS  PubMed  Google Scholar 

  10. Trimble CL. HPV infection-associated cancers: next-generation technology for diagnosis and treatment. Cancer Immunol Res. 2014;2(10):937–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–8.

    Article  PubMed  Google Scholar 

  12. Psyrri A, Cohen E. Oropharyngeal cancer: clinical implications of the HPV connection. Ann Oncol. 2011;22(5):997–9.

    Article  CAS  PubMed  Google Scholar 

  13. Jones TM. Tumour-infiltrating lymphocytes in the risk stratification of squamous cell carcinoma of the head and neck. Br J Cancer. 2014;110(2):269–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10.

    CAS  Google Scholar 

  15. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–44.

    Article  CAS  PubMed  Google Scholar 

  17. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomark Prev. 2008;17(7):1611–22.

    Article  CAS  Google Scholar 

  18. Hudson J, Bedell M, McCance D, Laiminis L. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol. 1990;64:519–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Werness BA, Parvatiyar P, Ramus SJ, et al. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst. 2000;92(13):1088–91.

    Article  CAS  PubMed  Google Scholar 

  20. Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003;31:35–40.

    Article  CAS  Google Scholar 

  21. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63(10):4417–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–9.

    Article  CAS  PubMed  Google Scholar 

  23. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15(1):361–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol. 1997;4(2):122–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Scherer EM, Smith RA, Gallego DF, et al. A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine. 2016;10:55–64.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8(9):e74797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer. 2000;88(1):92–8.

    Article  CAS  PubMed  Google Scholar 

  28. Nakagawa M, Stites DP, Patel S, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis. 2000;182(2):595–8.

    Article  CAS  PubMed  Google Scholar 

  29. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 1997;57(21):4855–61.

    CAS  PubMed  Google Scholar 

  30. Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother. 2010;59(5):799–803.

    Article  CAS  PubMed  Google Scholar 

  31. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67(1):354–61.

    Article  CAS  PubMed  Google Scholar 

  32. Valdespino V, Gorodezky C, Ortiz V, et al. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol. 2005;96(1):92–102.

    Article  PubMed  Google Scholar 

  33. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012;61(1):63–70.

    Article  PubMed  Google Scholar 

  34. de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004;64(15):5449–55.

    Article  PubMed  Google Scholar 

  35. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373–80.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fuchs K, Weitzen S, Wu L, Phipps MG, Boardman LA. Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J Pediatr Adolesc Gynecol. 2007;20(5):269–74.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Trimble CL, Clark RA, Thoburn C, et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol. 2010;185(11):7107–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Balermpas P, Rodel F, Rodel C, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2016;138(1):171–81.

    Article  CAS  PubMed  Google Scholar 

  41. Jung AC, Guihard S, Krugell S, et al. CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer. 2013;132(2):E26–36.

    Article  CAS  PubMed  Google Scholar 

  42. King EV, Ottensmeier CH, Thomas GJ. The immune response in HPV+ oropharyngeal cancer. Oncoimmunology. 2014;3(1):e27254.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil((R))): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74(11):1253–83.

    Article  CAS  PubMed  Google Scholar 

  45. Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016;126(1):5–11.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Erickson BK, Landers EE, Huh WK. Update on vaccination clinical trials for HPV-related disease. Clin Ther. 2014;36(1):8–16.

    Article  PubMed  Google Scholar 

  47. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130(2):264–8.

    Article  CAS  PubMed  Google Scholar 

  48. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103(2):317–26.

    Article  CAS  PubMed  Google Scholar 

  49. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4(155):155ra38.

    Article  Google Scholar 

  50. Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol. 2011;204(2):169 e1–8.

    Article  Google Scholar 

  52. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347(9014):1523–7.

    Article  CAS  PubMed  Google Scholar 

  53. Solares AM, Baladron I, Ramos T, et al. Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial Neoplasia: first-in-human, proof-of-concept trial. ISRN Obstet Gynecol. 2011;2011:292951.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6(9):3406–16.

    CAS  PubMed  Google Scholar 

  55. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999;35(6):946–52.

    Article  PubMed  Google Scholar 

  56. Cory L, Chu C. ADXS-HPV: a therapeutic listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother. 2014;10(11):3190–5.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Maldonado L, Teague JE, Morrow MP, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014;6(221):221ra13.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Vintermyr OK, Iversen O, Thoresen S, et al. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway. Gynecol Oncol. 2014;133(2):159–66.

    Article  CAS  PubMed  Google Scholar 

  59. Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44–55.

    Article  CAS  PubMed  Google Scholar 

  60. Draper LM, Kwong ML, Gros A, et al. Targeting of HPV-16+ epithelial cancer cells by TCR Gene engineered T cells directed against E6. Clin Cancer Res. 2015;21(19):4431–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Stevanovic S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bauml JM, Cohen RB, Aggarwal C. Immunotherapy for head and neck cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016;8(3):168–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet. 1998;351(9097):187–8.

    Article  CAS  PubMed  Google Scholar 

  65. Cho YS, Kang JW, Cho M, et al. Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett. 2001;501(2–3):139–45.

    Article  CAS  PubMed  Google Scholar 

  66. Huang SM, McCance DJ. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol. 2002;76(17):8710–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rosl F, Lengert M, Albrecht J, et al. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol. 1994;68(4):2142–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7(1):79–89.

    Article  CAS  PubMed  Google Scholar 

  69. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.

    Article  CAS  PubMed  Google Scholar 

  70. Hammes LS, Tekmal RR, Naud P, et al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation. Gynecol Oncol. 2007;105(1):157–65.

    Article  CAS  PubMed  Google Scholar 

  71. Utrera-Barillas D, Castro-Manrreza M, Castellanos E, et al. The role of macrophages and mast cells in lymphangiogenesis and angiogenesis in cervical carcinogenesis. Exp Mol Pathol. 2010;89(2):190–6.

    Article  CAS  PubMed  Google Scholar 

  72. Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006;19(3):481–91.

    Article  CAS  PubMed  Google Scholar 

  73. Herfs M, Herman L, Hubert P, et al. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother. 2009;58(4):603–14.

    Article  CAS  PubMed  Google Scholar 

  74. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002;169(6):3242–9.

    Article  CAS  PubMed  Google Scholar 

  75. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005;174(11):7172–8.

    Article  CAS  PubMed  Google Scholar 

  76. Woodham AW, Raff AB, Raff LM, et al. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014;192(10):4748–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Da Silva DM, Woodham AW, Skeate JG, et al. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized poly-I:C. Clin Immunol. 2015;161(2):197–208.

    Article  PubMed  Google Scholar 

  78. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol. 2015;15(12):731–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750–61.

    Article  CAS  PubMed  Google Scholar 

  80. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011;187(3):1157–65.

    Article  CAS  PubMed  Google Scholar 

  82. Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28(12):1594–602.

    Article  CAS  PubMed  Google Scholar 

  83. Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology. 2013;139(4):513–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.

    Article  CAS  PubMed  Google Scholar 

  85. Ayers MLJ, Nebozhyn M, Murphy E, Loboda A, Albright A, Cheng J, Kang P, Ebbinghaus S, Yearley J, Shankaran V, Seiwert T, Ribas A, McClanahan T. Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors. J Immunother Cancer. 2015;3(Suppl 2):P80.

    Article  PubMed Central  Google Scholar 

  86. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol. 2014;4:385.

    PubMed  Google Scholar 

  87. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641–8.

    Article  CAS  PubMed  Google Scholar 

  90. Chacon JA, Schutsky K, Powell DJ. The impact of chemotherapy, radiation and epigenetic modifiers in cancer cell expression of immune inhibitory and stimulatory molecules and anti-tumor efficacy. Vaccine. 2016;4(4):43.

    Article  Google Scholar 

  91. Szikriszt B, Poti A, Pipek O, et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 2016;17:99.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Sharma A, Bode B, Wenger RH, et al. Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One. 2011;6(11):e28217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Liao YP, Wang CC, Butterfield LH, et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004;173(4):2462–9.

    Article  CAS  PubMed  Google Scholar 

  94. Welters MJ, van der Sluis TC, van Meir H, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra52.

    Article  PubMed  Google Scholar 

  95. van Poelgeest MI, Welters MJ, van Esch EM, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16.

    Article  PubMed  Google Scholar 

  97. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007;85(9):719–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.

    Article  CAS  PubMed  Google Scholar 

  99. Angioli R, Lopez S, Aloisi A, et al. Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol. 2016;102:65–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology/Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Maria Agarwal & Cornelia Trimble

  2. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Cornelia Trimble

  3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Cornelia Trimble

Authors
  1. Maria Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelia Trimble
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelia Trimble .

Editor information

Editors and Affiliations

  1. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Laurence Zitvogel

  2. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Guido Kroemer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Agarwal, M., Trimble, C. (2018). Cancer Vaccines for HPV Malignancies. In: Zitvogel, L., Kroemer, G. (eds) Oncoimmunology. Springer, Cham. https://doi.org/10.1007/978-3-319-62431-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62431-0_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62430-3

  • Online ISBN: 978-3-319-62431-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation